These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
273 related articles for article (PubMed ID: 26539644)
21. A novel translational approach for human malignant pleural mesothelioma: heparanase-assisted dual virotherapy. Watanabe Y; Kojima T; Kagawa S; Uno F; Hashimoto Y; Kyo S; Mizuguchi H; Tanaka N; Kawamura H; Ichimaru D; Urata Y; Fujiwara T Oncogene; 2010 Feb; 29(8):1145-54. PubMed ID: 19935710 [TBL] [Abstract][Full Text] [Related]
22. What's the place of immunotherapy in malignant mesothelioma treatments? Grégoire M Cell Adh Migr; 2010; 4(1):153-61. PubMed ID: 20179421 [TBL] [Abstract][Full Text] [Related]
24. Oncolytic measles viruses for cancer therapy. Nakamura T; Russell SJ Expert Opin Biol Ther; 2004 Oct; 4(10):1685-92. PubMed ID: 15461580 [TBL] [Abstract][Full Text] [Related]
25. Success of measles virotherapy in ATL depends on type I interferon secretion and responsiveness. M Parrula MC; Fernandez SA; Landes K; Huey D; Lairmore M; Niewiesk S Virus Res; 2014 Aug; 189():206-13. PubMed ID: 24911240 [TBL] [Abstract][Full Text] [Related]
26. Recombinant measles virus induces cytolysis of cutaneous T-cell lymphoma in vitro and in vivo. Künzi V; Oberholzer PA; Heinzerling L; Dummer R; Naim HY J Invest Dermatol; 2006 Nov; 126(11):2525-32. PubMed ID: 16960554 [TBL] [Abstract][Full Text] [Related]
27. MicroRNA-Attenuated Clone of Virulent Semliki Forest Virus Overcomes Antiviral Type I Interferon in Resistant Mouse CT-2A Glioma. Martikainen M; Niittykoski M; von und zu Fraunberg M; Immonen A; Koponen S; van Geenen M; Vähä-Koskela M; Ylösmäki E; Jääskeläinen JE; Saksela K; Hinkkanen A J Virol; 2015 Oct; 89(20):10637-47. PubMed ID: 26269187 [TBL] [Abstract][Full Text] [Related]
28. Membrane dynamics and interactions in measles virus dendritic cell infections. Avota E; Koethe S; Schneider-Schaulies S Cell Microbiol; 2013 Feb; 15(2):161-9. PubMed ID: 22963539 [TBL] [Abstract][Full Text] [Related]
30. Overexpression and potential targeting of the oncofoetal antigen 5T4 in malignant pleural mesothelioma. Al-Taei S; Salimu J; Lester JF; Linnane S; Goonewardena M; Harrop R; Mason MD; Tabi Z Lung Cancer; 2012 Aug; 77(2):312-8. PubMed ID: 22498111 [TBL] [Abstract][Full Text] [Related]
31. Reply to: Oncolytic Viral Therapy for Malignant Pleural Mesothelioma. Jean D; Delaunay T; Meiller C; Boisgerault N; Grard M; Caruso S; Blanquart C; Felley-Bosco E; Bennouna J; Tangy F; Grégoire M; Fonteneau JF J Thorac Oncol; 2020 Jul; 15(7):e113-e116. PubMed ID: 32593448 [No Abstract] [Full Text] [Related]
32. Measles virus entry through the signaling lymphocyte activation molecule governs efficacy of mantle cell lymphoma radiovirotherapy. Miest TS; Frenzke M; Cattaneo R Mol Ther; 2013 Nov; 21(11):2019-31. PubMed ID: 23913184 [TBL] [Abstract][Full Text] [Related]
33. MAVS-dependent IRF3/7 bypass of interferon β-induction restricts the response to measles infection in CD150Tg mouse bone marrow-derived dendritic cells. Takaki H; Honda K; Atarashi K; Kobayashi F; Ebihara T; Oshiumi H; Matsumoto M; Shingai M; Seya T Mol Immunol; 2014 Feb; 57(2):100-10. PubMed ID: 24096085 [TBL] [Abstract][Full Text] [Related]
34. Susceptibility of human dendritic cells (DCs) to measles virus (MV) depends on their activation stages in conjunction with the level of CDw150: role of Toll stimulators in DC maturation and MV amplification. Murabayashi N; Kurita-Taniguchi M; Ayata M; Matsumoto M; Ogura H; Seya T Microbes Infect; 2002 Jul; 4(8):785-94. PubMed ID: 12270725 [TBL] [Abstract][Full Text] [Related]
35. Preclinical efficacy of the oncolytic measles virus expressing the sodium iodide symporter in iodine non-avid anaplastic thyroid cancer: a novel therapeutic agent allowing noninvasive imaging and radioiodine therapy. Reddi HV; Madde P; McDonough SJ; Trujillo MA; Morris JC; Myers RM; Peng KW; Russell SJ; McIver B; Eberhardt NL Cancer Gene Ther; 2012 Sep; 19(9):659-65. PubMed ID: 22790962 [TBL] [Abstract][Full Text] [Related]
36. Measles vaccine strains for virotherapy of non-small-cell lung carcinoma. Patel MR; Jacobson BA; Belgum H; Raza A; Sadiq A; Drees J; Wang H; Jay-Dixon J; Etchison R; Federspiel MJ; Russell SJ; Kratzke RA J Thorac Oncol; 2014 Aug; 9(8):1101-10. PubMed ID: 25157763 [TBL] [Abstract][Full Text] [Related]
37. Constitutive Interferon Pathway Activation in Tumors as an Efficacy Determinant Following Oncolytic Virotherapy. Kurokawa C; Iankov ID; Anderson SK; Aderca I; Leontovich AA; Maurer MJ; Oberg AL; Schroeder MA; Giannini C; Greiner SM; Becker MA; Thompson EA; Haluska P; Jentoft ME; Parney IF; Weroha SJ; Jen J; Sarkaria JN; Galanis E J Natl Cancer Inst; 2018 Oct; 110(10):1123-1132. PubMed ID: 29788332 [TBL] [Abstract][Full Text] [Related]
38. Immunostimulatory oncolytic activity of coxsackievirus A11 in human malignant pleural mesothelioma. Okamura K; Inoue H; Tanaka K; Ikematsu Y; Furukawa R; Ota K; Yoneshima Y; Iwama E; Okamoto I Cancer Sci; 2023 Mar; 114(3):1095-1107. PubMed ID: 36369966 [TBL] [Abstract][Full Text] [Related]